Skip to contents

Model and source

  • Citation: Purohit V, Huh Y, Wojciechowski J, Plotka A, Salts S, Antinew J, Dimitrova A, Nicholas T. Leveraging Prior Healthy Participant Pharmacokinetic Data to Evaluate the Impact of Renal and Hepatic Impairment on Ritlecitinib Pharmacokinetics. AAPS J. 2023;25(3):32. doi:10.1208/s12248-023-00792-8. PMCID PMC10047454. Parameter estimates from Supplementary Table B; model equations from the final-model NONMEM control stream (run12.mod) in Supplementary Text S1.
  • Description: Two-compartment population pharmacokinetic model with first-order absorption for oral ritlecitinib (PF-06651600, a covalent JAK3/TEC-family kinase inhibitor) in healthy participants and patients with rheumatoid arthritis. Apparent clearance and apparent central volume carry allometric body-weight scaling with exponents fixed at 0.75 and 1 referenced to 75 kg; apparent clearance is lower in rheumatoid arthritis patients and at total daily doses above 100 mg, and a high-fat meal slows absorption. Interindividual variability on CL/F and Vc/F is correlated, and the log-scale residual error differs between healthy participants and rheumatoid arthritis patients. This is the interim (fit-for-purpose) model used to simulate in silico healthy-participant reference cohorts for the ritlecitinib hepatic and renal impairment studies.
  • Article: https://doi.org/10.1208/s12248-023-00792-8

Ritlecitinib (PF-06651600) is an oral covalent, irreversible inhibitor of Janus kinase 3 (JAK3) and the TEC kinase family. Purohit 2023 reports the phase I hepatic impairment (moderate, Child-Pugh B; 30 mg QD) and renal impairment (severe, eGFR < 30 mL/min; 50 mg QD) studies. The healthy-participant arm of the renal study was never recruited because of the COVID-19 pause, so the authors generated in silico healthy-participant reference cohorts with an interim population PK model fitted to three earlier studies. That interim model, published in full (NONMEM control stream and parameter table) in Supplementary Text S1, is the model packaged here.

The later models of the same development programme – with an autoinhibitory Imax effect on clearance and bioavailability, fitted to far larger alopecia areata datasets – are packaged separately as Wojciechowski_2023_ritlecitinib_base, _updated and _final.

Population

The model was fitted to 1519 plasma ritlecitinib concentrations from 113 participants pooled from three studies (Supplementary Text S1 and Table A):

  • NCT02309827 – phase I single (5-800 mg) and multiple (50, 200, 400 mg QD; 100, 200 mg BID for 14 days) ascending-dose study in healthy participants, fasted (80 enrolled).
  • NCT02684760 – phase I relative-bioavailability and food-effect study in healthy participants: 50 mg tablet fasted, 50 mg oral solution fasted, 50 mg tablet after a high-fat meal (14 enrolled).
  • NCT02969044 – phase II study in moderate to severe active rheumatoid arthritis with an inadequate response to methotrexate: 200 mg QD for 8 weeks, fasted, sparse sampling (70 randomized, including placebo).

Baseline demographics of the modelling population are not reported. The two impairment studies that the model was used to support enrolled participants aged 18-75 years weighing more than 50 kg; Table I gives their demographics.

The same information is available programmatically via readModelDb("Purohit_2023_ritlecitinib")()$population.

Source trace

Every ini() entry in inst/modeldb/specificDrugs/Purohit_2023_ritlecitinib.R carries an in-file comment naming its origin. They are collected here for review.

Equation / parameter Value Source location
lka (ka) 3.48 1/h (95% CI 3.09-3.87) Supplementary Table B ‘ka’; control stream THETA(1)
lcl (CL/F at 75 kg) 78.1 L/h (70.3-86.0) Table B ‘CL/F’; THETA(2)
lvc (Vc/F at 75 kg) 119 L (99.7-138) Table B ‘V/F’; THETA(3)
lq (Q/F) 0.424 L/h (0.339-0.509) Table B ‘Q’; THETA(4)
lvp (Vp/F) 3.54 L (3.12-3.97) Table B ‘Vp/F’; THETA(5)
e_wt_cl 0.75 (not estimated) Text S1 ‘Structural Model Development’; control stream (BWT/75)**0.75
e_wt_vc 1 (not estimated) Text S1; control stream TVV2 = THETA(3)*(BWT/75)
e_dose_high_cl log(0.666) Table B ‘Dose on CL/F’ = 0.666 (0.641-0.691); THETA(7)
e_dis_ra_cl log(0.625) Table B ‘RA on CL/F’ = 0.625 (0.564-0.739); THETA(10)
e_fed_highfat_ka -0.613 Table B ‘Food on ka’ = -0.613 (-0.649 to -0.577); THETA(9)
var(etalcl) 0.156^2 = 0.024336 Table B ‘IIV-CL/F’ = 0.156, read as an SD (see below)
cov(etalcl, etalvc) 0.173 x 0.156 x 0.280 = 0.00755664 Table B ‘Cov CL/F-V/F’ = 0.173, read as a correlation
var(etalvc) 0.280^2 = 0.0784 Table B ‘IIV-V/F’ = 0.280, read as an SD
expSdHv sqrt(0.166) = 0.407 Table B ‘RUV-HP’ (a $SIGMA variance)
expSdRa sqrt(0.860) = 0.927 Table B ‘RUV-RA’ (a $SIGMA variance)
ka KA = THETA(1)*(1 + FED*THETA(9)) control stream $PK (FLG3 = 0 IF (FOOD.NE.0))
CL/F THETA(2) * THETA(7)^[TDD > 100] * (BWT/75)^0.75 * THETA(10)^RA * exp(ETA(1)) control stream $PK (TRT = DOSE*DFREQ)
Vc/F THETA(3) * (BWT/75) * exp(ETA(2)) control stream $PK
Absorption lag none (ALAG1 THETAs 6 and 8 are 0 FIX) control stream $PK and $THETA
Cc (ng/mL) 1000 * central / vc control stream S2 = V2/1000
Residual error log(DV) = log(Cc) + eps, SD by population control stream $ERROR

Reading the variability rows of Table B

Table B’s footnote calls the IIV rows ‘inter-individual variance’, and the off-diagonal row is labelled ‘Cov CL/F-V/F’. Taken literally (variances 0.156 and 0.280, covariance 0.173) the block is positive definite, so the label cannot be excluded on arithmetic alone. It does, however, contradict the paper’s own simulation: under that reading the 90% prediction interval of the trial geometric-mean AUC0-24 in Table IV comes out about 2.2-fold too wide, and the implied 45% CV of AUC in healthy participants is far above the 16% observed in the eight Study 1 healthy participants (Table II).

The packaged model therefore reads the IIV rows as NONMEM’s correlation-matrix print – SDs of 0.156 (CL/F) and 0.280 (Vc/F) on the diagonal, correlation 0.173 off it – and keeps the residual-error rows as the labelled $SIGMA variances (0.166 and 0.860, log-scale SDs 0.407 and 0.927). Reading the residual-error rows as SDs as well narrows the AUC interval further but leaves the simulated Table IV Cmax medians about 15% short. The section Scale of the variability rows below repeats the Table IV simulation under all three readings. The chosen magnitudes are also in line with the later model of the same programme fitted to overlapping data (Wojciechowski_2023_ritlecitinib_base: healthy-participant IIV SD on CL/F 0.201 and on Vc/F 0.113, proportional residual SD 0.340).

Because the control stream fits log-transformed concentrations with an additive epsilon (Y = LOG(F) + EPS), the log-scale residual SD for lnorm() is the square root of each $SIGMA variance.

Deterministic covariate checks

The covariate model is a set of multiplicative switches, so each published coefficient can be verified exactly from typical-value parameters.

mod <- readModelDb("Purohit_2023_ritlecitinib")
mod_typ <- rxode2::zeroRe(mod)
#> ℹ parameter labels from comments will be replaced by 'label()'
#> Warning: No sigma parameters in the model

cov_grid <- tibble::tribble(
  ~scenario,                          ~WT, ~DIS_RA, ~DOSE_HIGH, ~FED_HIGHFAT,
  "Reference (75 kg healthy, fasted)",  75,       0,          0,            0,
  "100 kg healthy",                    100,       0,          0,            0,
  "Rheumatoid arthritis",               75,       1,          0,            0,
  "Total daily dose > 100 mg",          75,       0,          1,            0,
  "High-fat meal",                      75,       0,          0,            1
) |>
  mutate(id = row_number())

ev_cov <- cov_grid |>
  select(id, WT, DIS_RA, DOSE_HIGH, FED_HIGHFAT) |>
  mutate(time = 0, amt = 0, evid = 0, cmt = "central")

par_typ <- rxode2::rxSolve(mod_typ, ev_cov, returnType = "data.frame") |>
  select(id, ka, cl, vc) |>
  left_join(cov_grid |> select(id, scenario), by = "id")
#> ℹ omega/sigma items treated as zero: 'etalcl', 'etalvc'
#> Warning: multi-subject simulation without without 'omega'

expected <- tibble::tibble(
  scenario = cov_grid$scenario,
  ka_exp = 3.48 * c(1, 1, 1, 1, 1 - 0.613),
  cl_exp = 78.1 * c(1, (100 / 75)^0.75, 0.625, 0.666, 1),
  vc_exp = 119 * c(1, 100 / 75, 1, 1, 1)
)

par_chk <- par_typ |>
  left_join(expected, by = "scenario") |>
  select(scenario, ka, ka_exp, cl, cl_exp, vc, vc_exp)

par_chk |>
  dplyr::rename(
    Scenario = scenario,
    "ka (1/h)" = ka, "ka expected" = ka_exp,
    "CL/F (L/h)" = cl, "CL/F expected" = cl_exp,
    "Vc/F (L)" = vc, "Vc/F expected" = vc_exp
  ) |>
  knitr::kable(digits = 3, caption = "Typical-value parameters against the coefficients of Supplementary Table B.")
Typical-value parameters against the coefficients of Supplementary Table B.
Scenario ka (1/h) ka expected CL/F (L/h) CL/F expected Vc/F (L) Vc/F expected
Reference (75 kg healthy, fasted) 3.480 3.480 78.100 78.100 119.000 119.000
100 kg healthy 3.480 3.480 96.907 96.907 158.667 158.667
Rheumatoid arthritis 3.480 3.480 48.812 48.812 119.000 119.000
Total daily dose > 100 mg 3.480 3.480 52.015 52.015 119.000 119.000
High-fat meal 1.347 1.347 78.100 78.100 119.000 119.000

# Typical-value solve against its own closed form: the only difference is
# floating-point rounding, so a tight bound is correct here.
stopifnot(
  max(abs(par_chk$ka / par_chk$ka_exp - 1)) < 1e-6,
  max(abs(par_chk$cl / par_chk$cl_exp - 1)) < 1e-6,
  max(abs(par_chk$vc / par_chk$vc_exp - 1)) < 1e-6
)

The reference typical CL/F of 78.1 L/h at 75 kg matches the observed geometric mean CL/F of the Study 1 healthy participants, 78.20 L/h (Table II, mean weight 79.1 kg).

Steady-state AUC identity

For a linear model with complete absorption, the steady-state AUC over a dosing interval equals Dose / (CL/F). Day 10 of once-daily dosing is at steady state (the slowest disposition half-life, of the small peripheral compartment, is about 6 h), so the PKNCA AUC0-24 of a typical-value solve must reproduce it.

tad_grid <- c(seq(0, 2, by = 0.05), seq(2.25, 24, by = 0.25))
ss_doses <- c(30, 50, 200)
ev_ss <- bind_rows(lapply(seq_along(ss_doses), function(i) {
  rxode2::et(amt = ss_doses[i], ii = 24, addl = 9, cmt = "depot") |>
    rxode2::et(216 + tad_grid, cmt = "central") |>
    as.data.frame() |>
    mutate(id = i, dose_mg = ss_doses[i])
})) |>
  mutate(WT = 75, DIS_RA = 0, FED_HIGHFAT = 0, DOSE_HIGH = as.numeric(dose_mg > 100))

sim_ss <- rxode2::rxSolve(mod_typ, ev_ss, keep = c("dose_mg"), returnType = "data.frame") |>
  mutate(tad = time - 216, regimen = paste(dose_mg, "mg QD"))
#> ℹ omega/sigma items treated as zero: 'etalcl', 'etalvc'
#> Warning: multi-subject simulation without without 'omega'

conc_ss <- sim_ss |>
  filter(!is.na(Cc)) |>
  select(id, regimen, tad, Cc)
dose_ss <- sim_ss |>
  distinct(id, regimen, dose_mg) |>
  mutate(tad = 0)

nca_ss <- PKNCA::pk.nca(PKNCA::PKNCAdata(
  PKNCA::PKNCAconc(conc_ss, Cc ~ tad | regimen + id),
  PKNCA::PKNCAdose(dose_ss, dose_mg ~ tad | regimen + id),
  intervals = data.frame(start = 0, end = 24, auclast = TRUE, cmax = TRUE, tmax = TRUE),
  options = list(auc.method = "lin up/log down")
))

ss_chk <- as.data.frame(nca_ss$result) |>
  filter(PPTESTCD == "auclast") |>
  select(regimen, auc_nca = PPORRES) |>
  left_join(
    sim_ss |> distinct(regimen, dose_mg, cl),
    by = "regimen"
  ) |>
  mutate(auc_closed = 1000 * dose_mg / cl, pct_diff = 100 * (auc_nca / auc_closed - 1))

ss_chk |>
  dplyr::rename(
    Regimen = regimen, "AUC0-24 PKNCA (ng*h/mL)" = auc_nca, "Dose (mg)" = dose_mg,
    "CL/F (L/h)" = cl, "Dose/CL (ng*h/mL)" = auc_closed, "% diff" = pct_diff
  ) |>
  knitr::kable(digits = 2, caption = "Steady-state AUC0-24 from PKNCA against Dose / CL for 75 kg healthy participants.")
Steady-state AUC0-24 from PKNCA against Dose / CL for 75 kg healthy participants.
Regimen AUC0-24 PKNCA (ng*h/mL) Dose (mg) CL/F (L/h) Dose/CL (ng*h/mL) % diff
200 mg QD 3843.75 200 52.01 3845.07 -0.03
30 mg QD 383.92 30 78.10 384.12 -0.05
50 mg QD 639.86 50 78.10 640.20 -0.05

# Deterministic solve versus its closed form: numerical integration and the
# trapezoidal rule on a 0.05-0.25 h grid are the only error sources.
stopifnot(max(abs(ss_chk$pct_diff)) < 1)

The 200 mg QD row shows the dose nonlinearity of the interim model: above 100 mg/day the typical CL/F drops to 52.0 L/h, so steady-state AUC rises by 1.5-fold more than dose-proportionally.

Replicating Table IV: in silico healthy-participant cohorts

Purohit 2023 simulated 1000 trials of eight healthy participants for each impairment study. Body weight was drawn uniformly from 69.9-99.9 kg (Study 1) or 73-103 kg (Study 2); each participant received the study dose once daily for 10 days; concentrations with residual error applied were sampled on day 10 at the protocol times; and AUC0-24 was computed with the linear-up/log-down rule in PKNCA. The trial geometric means were then summarised by their median and 90% prediction interval, and each trial’s geometric mean was compared with the observed impairment cohort.

Here a single cohort of 200 healthy participants per study is simulated, and the 1000 eight-participant trials are formed by resampling from it.

rxode2::rxSetSeed(20230327)
set.seed(20230327)

n_per_study <- 200

make_cohort <- function(study, dose, wt_lo, wt_hi, sample_times, id_offset) {
  base <- rxode2::et(amt = dose, ii = 24, addl = 9, cmt = "depot") |>
    rxode2::et(216 + sample_times, cmt = "central") |>
    as.data.frame()
  wt <- runif(n_per_study, wt_lo, wt_hi)
  dplyr::bind_rows(lapply(seq_len(n_per_study), function(i) {
    out <- base
    out$id <- id_offset + i
    out$WT <- wt[i]
    out
  })) |>
    mutate(study = study, dose_mg = dose, DIS_RA = 0, FED_HIGHFAT = 0, DOSE_HIGH = 0)
}

# Day-10 sampling schedules of the two protocols (Methods, Study Design).
ev_s1 <- make_cohort("Study 1 (30 mg QD)", 30, 69.9, 99.9,
                     c(0, 0.5, 1, 2, 3, 4, 6, 8, 12, 14, 24), 0)
ev_s2 <- make_cohort("Study 2 (50 mg QD)", 50, 73, 103,
                     c(0, 0.25, 0.5, 1, 2, 4, 6, 8, 12, 16, 24), 10000)
ev_insilico <- bind_rows(ev_s1, ev_s2)

sim_insilico <- rxode2::rxSolve(
  mod, ev_insilico,
  keep = c("study", "dose_mg"),
  returnType = "data.frame"
) |>
  mutate(tad = time - 216)
#> ℹ parameter labels from comments will be replaced by 'label()'
# Per-subject day-10 NCA. `sim` is the concentration with residual error
# applied, as in the paper.
subject_nca <- function(sim_df) {
  conc <- sim_df |>
    filter(!is.na(sim)) |>
    select(id, study, tad, conc = sim)
  doses <- sim_df |>
    distinct(id, study, dose_mg) |>
    mutate(tad = 0)
  res <- PKNCA::pk.nca(PKNCA::PKNCAdata(
    PKNCA::PKNCAconc(conc, conc ~ tad | study + id),
    PKNCA::PKNCAdose(doses, dose_mg ~ tad | study + id),
    intervals = data.frame(start = 0, end = 24, auclast = TRUE, cmax = TRUE, tmax = TRUE),
    options = list(auc.method = "lin up/log down")
  ))
  as.data.frame(res$result) |>
    filter(PPTESTCD %in% c("auclast", "cmax")) |>
    select(id, study, PPTESTCD, PPORRES) |>
    tidyr::pivot_wider(names_from = PPTESTCD, values_from = PPORRES)
}

# Observed impairment-cohort geometric means (Table II / Table IV).
observed <- tibble::tibble(
  study = c("Study 1 (30 mg QD)", "Study 2 (50 mg QD)"),
  obs_auc = c(454.5, 986.3),
  obs_cmax = c(194.3, 445.6)
)

# 1000 resampled trials of 8 participants per study (no new simulation),
# summarised as in Table IV.
n_trials <- 1000
gmean <- function(x) exp(mean(log(x)))
q <- function(x, p) unname(stats::quantile(x, p))
summarise_trials <- function(subj) {
  trials <- bind_rows(lapply(split(subj, subj$study), function(d) {
    bind_rows(lapply(seq_len(n_trials), function(k) {
      pick <- d[sample.int(nrow(d), 8, replace = TRUE), ]
      tibble::tibble(study = d$study[1], trial = k,
                     auclast = gmean(pick$auclast), cmax = gmean(pick$cmax))
    }))
  }))
  trials |>
    left_join(observed, by = "study") |>
    group_by(study) |>
    summarise(
      auc_med = median(auclast), auc_lo = q(auclast, 0.05), auc_hi = q(auclast, 0.95),
      cmax_med = median(cmax), cmax_lo = q(cmax, 0.05), cmax_hi = q(cmax, 0.95),
      gmr_auc_med = median(obs_auc / auclast),
      gmr_auc_lo = q(obs_auc / auclast, 0.05), gmr_auc_hi = q(obs_auc / auclast, 0.95),
      gmr_cmax_med = median(obs_cmax / cmax),
      gmr_cmax_lo = q(obs_cmax / cmax, 0.05), gmr_cmax_hi = q(obs_cmax / cmax, 0.95),
      pct_gmr_ge2 = 100 * mean(obs_auc / auclast >= 2),
      .groups = "drop"
    )
}

trial_summary <- summarise_trials(subject_nca(sim_insilico))

published <- tibble::tibble(
  study = c("Study 1 (30 mg QD)", "Study 2 (50 mg QD)"),
  auc_pub = c("345 (309-388)", "578 (515-650)"),
  cmax_pub = c("184 (152-222)", "314 (262-372)"),
  gmr_auc_pub = c("1.32 (1.17-1.47)", "1.71 (1.52-1.92)"),
  gmr_cmax_pub = c("1.06 (0.87-1.28)", "1.42 (1.20-1.70)"),
  pct_ge2_pub = c(0, 1)
)

fmt <- function(m, lo, hi, d = 0) {
  sprintf(paste0("%.", d, "f (%.", d, "f-%.", d, "f)"), m, lo, hi)
}
trial_summary |>
  left_join(published, by = "study") |>
  transmute(
    study,
    auc_sim = fmt(auc_med, auc_lo, auc_hi), auc_pub,
    cmax_sim = fmt(cmax_med, cmax_lo, cmax_hi), cmax_pub,
    gmr_auc_sim = fmt(gmr_auc_med, gmr_auc_lo, gmr_auc_hi, 2), gmr_auc_pub,
    gmr_cmax_sim = fmt(gmr_cmax_med, gmr_cmax_lo, gmr_cmax_hi, 2), gmr_cmax_pub,
    pct_gmr_ge2, pct_ge2_pub
  ) |>
  dplyr::rename(
    Study = study,
    "AUC0-24 GM, simulated" = auc_sim, "AUC0-24 GM, Table IV" = auc_pub,
    "Cmax GM, simulated" = cmax_sim, "Cmax GM, Table IV" = cmax_pub,
    "AUC GMR, simulated" = gmr_auc_sim, "AUC GMR, Table IV" = gmr_auc_pub,
    "Cmax GMR, simulated" = gmr_cmax_sim, "Cmax GMR, Table IV" = gmr_cmax_pub,
    "% trials AUC GMR >= 2, simulated" = pct_gmr_ge2,
    "% trials AUC GMR >= 2, Table IV" = pct_ge2_pub
  ) |>
  knitr::kable(digits = 1, caption = "Replicates Table IV of Purohit 2023: median (90% PI) of 1000 trial geometric means (GM) of eight in silico healthy participants, and of the geometric mean ratios (GMR) of the observed impairment cohort to each trial.")
Replicates Table IV of Purohit 2023: median (90% PI) of 1000 trial geometric means (GM) of eight in silico healthy participants, and of the geometric mean ratios (GMR) of the observed impairment cohort to each trial.
Study AUC0-24 GM, simulated AUC0-24 GM, Table IV Cmax GM, simulated Cmax GM, Table IV AUC GMR, simulated AUC GMR, Table IV Cmax GMR, simulated Cmax GMR, Table IV % trials AUC GMR >= 2, simulated % trials AUC GMR >= 2, Table IV
Study 1 (30 mg QD) 349 (298-404) 345 (309-388) 180 (145-220) 184 (152-222) 1.30 (1.12-1.53) 1.32 (1.17-1.47) 1.08 (0.88-1.34) 1.06 (0.87-1.28) 0.0 0
Study 2 (50 mg QD) 590 (510-677) 578 (515-650) 317 (256-395) 314 (262-372) 1.67 (1.46-1.94) 1.71 (1.52-1.92) 1.40 (1.13-1.74) 1.42 (1.20-1.70) 2.3 1

Comparison against published NCA

sim_wide <- trial_summary |>
  select(study, auclast = auc_med, cmax = cmax_med)
ref_wide <- tibble::tibble(
  study = c("Study 1 (30 mg QD)", "Study 2 (50 mg QD)"),
  auclast = c(345, 578),
  cmax = c(184, 314)
)
cmp <- nlmixr2lib::ncaComparisonTable(
  sim_wide, ref_wide,
  by = "study",
  units = c(auclast = "ng*h/mL", cmax = "ng/mL")
)
knitr::kable(cmp, caption = "Median trial geometric mean of day-10 AUC0-24 and Cmax for in silico healthy participants: Table IV versus this simulation.")
Median trial geometric mean of day-10 AUC0-24 and Cmax for in silico healthy participants: Table IV versus this simulation.
NCA parameter study Reference Simulated % diff
Cmax (ng/mL) Study 1 (30 mg QD) 184 180 -2.0%
Cmax (ng/mL) Study 2 (50 mg QD) 314 317 +1.0%
AUClast (ng*h/mL) Study 1 (30 mg QD) 345 349 +1.2%
AUClast (ng*h/mL) Study 2 (50 mg QD) 578 590 +2.1%
if (!is.null(attr(cmp, "footnote"))) cat(attr(cmp, "footnote"))

pct <- function(sim, ref) 100 * (sim / ref - 1)
stopifnot(
  # Structural: a mis-transcribed CL/F, Vc/F, dose, unit or allometric
  # reference moves the centre of the trial distribution by tens of percent.
  # The median of 1000 resampled trial means is a centre statistic, so it
  # is robust to which simulated subjects land in the tails.
  all(abs(pct(trial_summary$auc_med, ref_wide$auclast)) < 15),
  all(abs(pct(trial_summary$cmax_med, ref_wide$cmax)) < 20),
  # The decision the paper drew from Table IV: the median AUC GMR stays
  # below 2 for both impairment studies.
  all(trial_summary$gmr_auc_med < 2)
)

The simulated medians reproduce Table IV for both studies. The Study 1 validation result – the observed AUC0-24 GMR of 1.19 lies inside the 90% PI of the in silico GMR – is reproduced as well.

Scale of the variability rows

The Table IV simulation is repeated below with the same event table under the two readings of Table B that the packaged model rejects (see Reading the variability rows of Table B):

  • As labelled: IIV variances 0.156 and 0.280 with covariance 0.173; residual-error variances 0.166 and 0.860.
  • All SD: IIV and residual-error rows all read as SDs, with a correlation of 0.173.

The packaged model is the third, mixed reading. The width of a 90% PI is compared with Table IV on the log scale, as log(upper / lower) relative to the published log(upper / lower).

mod_labelled <- rxode2::ini(
  mod,
  etalcl + etalvc ~ c(0.156, 0.173, 0.280)
)
#> ℹ parameter labels from comments will be replaced by 'label()'
#> ℹ some correlations may have been dropped for the variables: `etalcl`, `etalvc`
#> ℹ the piping should specify the needed covariances directly
#> ℹ change initial estimate of `etalcl` to `0.156`
#> ℹ add covariance between `etalvc` and `etalcl` with initial estimate `0.173`
#> ℹ change initial estimate of `etalvc` to `0.28`
mod_all_sd <- rxode2::ini(
  mod,
  expSdHv = 0.166,
  expSdRa = 0.860
)
#> ℹ parameter labels from comments will be replaced by 'label()'
#> ℹ change initial estimate of `expSdHv` to `0.166`
#> ℹ change initial estimate of `expSdRa` to `0.86`

run_reading <- function(m, seed) {
  rxode2::rxSetSeed(seed)
  set.seed(seed)
  rxode2::rxSolve(m, ev_insilico, keep = c("study", "dose_mg"), returnType = "data.frame") |>
    mutate(tad = time - 216) |>
    subject_nca() |>
    summarise_trials()
}

readings <- bind_rows(
  trial_summary |> mutate(reading = "Mixed (packaged)"),
  run_reading(mod_labelled, 101) |> mutate(reading = "As labelled"),
  run_reading(mod_all_sd, 202) |> mutate(reading = "All SD")
)

pub_num <- tibble::tibble(
  study = c("Study 1 (30 mg QD)", "Study 2 (50 mg QD)"),
  auc_pub_med = c(345, 578), auc_pub_lo = c(309, 515), auc_pub_hi = c(388, 650),
  cmax_pub_med = c(184, 314), cmax_pub_lo = c(152, 262), cmax_pub_hi = c(222, 372)
)

reading_chk <- readings |>
  left_join(pub_num, by = "study") |>
  mutate(
    auc_med_pct = 100 * (auc_med / auc_pub_med - 1),
    auc_width_ratio = log(auc_hi / auc_lo) / log(auc_pub_hi / auc_pub_lo),
    cmax_med_pct = 100 * (cmax_med / cmax_pub_med - 1),
    cmax_width_ratio = log(cmax_hi / cmax_lo) / log(cmax_pub_hi / cmax_pub_lo)
  )

reading_chk |>
  transmute(
    reading, study,
    auc = fmt(auc_med, auc_lo, auc_hi), auc_med_pct, auc_width_ratio,
    cmax = fmt(cmax_med, cmax_lo, cmax_hi), cmax_med_pct, cmax_width_ratio
  ) |>
  dplyr::rename(
    Reading = reading, Study = study,
    "AUC0-24 GM median (90% PI)" = auc, "AUC median vs Table IV (%)" = auc_med_pct,
    "AUC PI width / Table IV" = auc_width_ratio,
    "Cmax GM median (90% PI)" = cmax, "Cmax median vs Table IV (%)" = cmax_med_pct,
    "Cmax PI width / Table IV" = cmax_width_ratio
  ) |>
  knitr::kable(digits = 2, caption = "Table IV reproduced under three readings of the Table B variability rows. Published: AUC0-24 345 (309-388) and 578 (515-650); Cmax 184 (152-222) and 314 (262-372).")
Table IV reproduced under three readings of the Table B variability rows. Published: AUC0-24 345 (309-388) and 578 (515-650); Cmax 184 (152-222) and 314 (262-372).
Reading Study AUC0-24 GM median (90% PI) AUC median vs Table IV (%) AUC PI width / Table IV Cmax GM median (90% PI) Cmax median vs Table IV (%) Cmax PI width / Table IV
Mixed (packaged) Study 1 (30 mg QD) 349 (298-404) 1.16 1.34 180 (145-220) -2.05 1.09
Mixed (packaged) Study 2 (50 mg QD) 590 (510-677) 2.14 1.22 317 (256-395) 1.00 1.24
As labelled Study 1 (30 mg QD) 335 (256-431) -3.00 2.29 177 (127-251) -4.01 1.81
As labelled Study 2 (50 mg QD) 633 (503-787) 9.55 1.92 332 (242-449) 5.77 1.77
All SD Study 1 (30 mg QD) 345 (308-381) 0.13 0.94 162 (140-187) -11.87 0.75
All SD Study 2 (50 mg QD) 554 (489-625) -4.08 1.06 247 (213-288) -21.31 0.86

chk_of <- function(r) filter(reading_chk, reading == r)
stopifnot(
  # Each statistic is averaged over the two studies so that one study's
  # sampling scatter cannot decide the outcome. The PI width is set by the
  # per-subject spread of 200 simulated subjects, whose SD carries a ~5%
  # sampling error; the expected ratios are about 2.1 (as labelled) and 1.3
  # (mixed), so a 1.7 boundary leaves wide margins on both sides.
  mean(chk_of("As labelled")$auc_width_ratio) > 1.7,
  mean(chk_of("Mixed (packaged)")$auc_width_ratio) < 1.7,
  # Reading the residual error as SDs leaves the Cmax centre about 15% short;
  # the median of 1000 trial means has ~2% sampling error per study.
  mean(chk_of("All SD")$cmax_med_pct) < -8,
  all(abs(chk_of("Mixed (packaged)")$cmax_med_pct) < 10)
)

Only the mixed reading reproduces both the location of every Table IV summary and the spread of the AUC0-24 distribution to within about a third. The literal reading roughly doubles the spread, and the all-SD reading misses the Cmax centre.

Day-10 concentration-time profiles

sim_insilico |>
  filter(!is.na(Cc)) |>
  group_by(study, tad) |>
  summarise(
    p05 = quantile(Cc, 0.05), p50 = median(Cc), p95 = quantile(Cc, 0.95),
    .groups = "drop"
  ) |>
  ggplot(aes(tad, p50, colour = study, fill = study)) +
  geom_ribbon(aes(ymin = p05, ymax = p95), alpha = 0.2, colour = NA) +
  geom_line() +
  geom_point() +
  scale_y_log10() +
  labs(x = "Time after the day-10 dose (h)", y = "Ritlecitinib (ng/mL)",
       colour = NULL, fill = NULL) +
  theme_bw()
Simulated day-10 ritlecitinib plasma concentrations (median and 90% interval of individual predictions, 200 in silico healthy participants per study) at the protocol sampling times.

Simulated day-10 ritlecitinib plasma concentrations (median and 90% interval of individual predictions, 200 in silico healthy participants per study) at the protocol sampling times.

Assumptions and deviations

  • Interim model. Purohit 2023 describes this as a fit-for-purpose iteration of the ritlecitinib population PK model, used before the final model was available. The final development models, which replace the dose switch with a concentration-driven autoinhibition of clearance and bioavailability, are packaged as the Wojciechowski_2023_ritlecitinib_* models.
  • Allometric scaling of Q/F and Vp/F. Supplementary Text S1 (‘Structural Model Development’) says weight scaling was applied to Q/F and Vp/F as well as CL/F and Vc/F, but the final-model control stream (Q = THETA(4), V3 = THETA(5)) and the ‘Final Model’ paragraph scale only CL/F and Vc/F. The control stream is followed.
  • No absorption lag. The control stream carries ALAG1 = THETA(6) + FED*THETA(8) with both THETAs 0 FIX, so the lag is identically zero and is not coded.
  • Food covariate. The control-stream flag is any non-zero FOOD value, and the supplement states the effect was assessed in participants with a recorded high-fat meal (the food-effect arm of NCT02684760); participants without a recorded food status were grouped with the fasted. It is therefore mapped to FED_HIGHFAT.
  • Dose switch. DOSE_HIGH is defined on the total daily dose (TRT = DOSE*DFREQ > 100 mg), so 100 mg BID is in the high group.
  • Scale of the IIV rows (departure from the printed label). Table B’s footnote calls the IIV rows variances, but the maintainers read them as SDs (0.156 on CL/F, 0.280 on Vc/F) with a correlation of 0.173, as printed in NONMEM’s correlation matrix. The evidence is the paper’s own Table IV, which only this reading reproduces (see Scale of the variability rows). The magnitudes also agree with the healthy-participant IIV of the later Wojciechowski_2023_ritlecitinib_base model (SD 0.201 on CL/F and 0.113 on Vc/F), and with the 16% CV of AUC observed in the Study 1 healthy participants. The labelled reading would imply about 45% CV.
  • Residual error. The residual-error rows are kept as the labelled $SIGMA variances of the log-transformed-both-sides model; expSdHv and expSdRa are their square roots (0.407 and 0.927). The healthy-participant value is close to the 0.340 proportional residual SD of the Wojciechowski 2023 base model.
  • In silico cohorts. The paper drew fresh weights for every one of 1000 trials; here 200 participants per study are simulated once and the trials are resampled from them, which reproduces the trial-to-trial distribution of the geometric mean without simulating 8000 participants. The food state on dosing days 1-9 (non-fasting in the studies) is not stated for the simulation; all doses are simulated fasted, which only alters ka and has no material effect on day-10 exposure. The assay lower limit of quantification is not reported, so concentrations were not censored to zero as the paper did.